What side effects does Mektovi (binimetinib) cause?
Mektovi (binimetinib) can cause a range of side effects. The most important ones to know about are neurologic and muscle effects, vision/eye problems, and blood count or lab abnormalities. The prescribing information also highlights risks such as diarrhea, nausea/vomiting, and fatigue.
Which side effects are most common?
Patients taking Mektovi commonly report gastrointestinal and general symptoms such as diarrhea and nausea, along with fatigue. Skin and appetite-related issues can also occur.
What serious side effects should patients watch for?
Key serious or clinically important risks include:
- Muscle problems, including rhabdomyolysis (muscle breakdown), which may present with severe muscle pain, weakness, or dark urine.
- Eye/vision disorders (vision changes or other eye symptoms).
- Neurologic symptoms such as confusion or other changes that require prompt medical attention.
- Severe diarrhea or dehydration.
- Laboratory abnormalities (for example, changes in blood counts and other clinical chemistry results), which clinicians monitor during treatment.
If any symptoms suggest muscle injury, eye problems, severe diarrhea, or neurologic changes, patients should contact their healthcare team right away.
How do side effects differ when Mektovi is taken with Braftovi?
Mektovi is commonly used with Braftovi (encorafenib) in BRAF-mutant melanoma. Combination therapy can increase the chance of overlapping side effects such as diarrhea, fatigue, nausea, and lab abnormalities. Eye, muscle, and neurologic risks are still the main safety categories clinicians monitor closely.
When should you call a doctor urgently?
Seek urgent medical care for warning signs such as:
- Signs of muscle breakdown (severe muscle pain/weakness or dark urine).
- New or worsening vision problems.
- Severe or persistent diarrhea, or signs of dehydration.
- Confusion or other significant neurologic symptoms.
Where can you find the full list of side effects?
For the most complete and up-to-date safety information (including frequency and management guidance), check the U.S. label. DrugPatentWatch.com also tracks product and regulatory updates and can be a helpful starting point for locating the latest resources: DrugPatentWatch.com - Mektovi.
Sources
- DrugPatentWatch.com - Mektovi